| Xiannuoxin (simnotrelvir) / Simcere, Shanghai Inst. of Materia Medica |
ChiCTR2200062792: A Multicenter, Randomized, Double-blind, Phase II/III Clinical Study to Evaluate the Efficacy and Safety of SIM0417 Orally Co-Administered with Ritonavir in Symptomatic Adult Participants with Mild to Moderate COVID-19 |
|
|
| Not yet recruiting | 3 | 1200 | | orally administrated SIM0417+ ritonavir ;SIM0417 tablet, ritonavir tablet | China-Japan Friendship Hospital; Jiangsu Xiansheng Pharmaceutical Co., Ltd., self-finance | COVID-19 | | | | |
NCT05506176: A Clinical Study to Evaluate the Efficacy and Safety of SIM0417 Orally Co-Administered With Ritonavir in Symptomatic Adult Participants With Mild to Moderate COVID-19 |
|
|
| Completed | 2/3 | 1208 | RoW | SIM0417, Simnotrelvir, Placebo | Jiangsu Simcere Pharmaceutical Co., Ltd. | COVID-19 | 01/23 | 03/23 | | |
NCT05373433: To Evaluate SSD8432/Ritonavir in Adults With COVID-19 |
|
|
| Not yet recruiting | 2/3 | 670 | NA | SSD8432 750mg, Ritonavir 100mg, SSD8432 placebo, Ritonavir placebo | Jiangsu Simcere Pharmaceutical Co., Ltd. | COVID-19 | 05/23 | 10/23 | | |
NCT05373446: Evaluation of SSD8432 and Ritonavir in Adult Subjects With COVID-19 Clinical Study |
|
|
| Not yet recruiting | 2 | 72 | NA | SSD8432 300mg, ritonavir 100mg, SSD8432 750mg, SSD8432Placebo, ritonavir placebo | Jiangsu Simcere Pharmaceutical Co., Ltd. | COVID-19 | 10/22 | 03/23 | | |
NCT05369676: To Evaluate SSD8432/ Ritonavir in Adults With COVID-19 |
|
|
| Completed | 1/2 | 32 | RoW | SSD8432 dose 1/Ritonavir, SIM0417 dose 1/Ritonavir, SSD8432 dose 2/Ritonavir, SIM0417 dose 2/Ritonavir | Jiangsu Simcere Pharmaceutical Co., Ltd. | COVID-19 Patients | 08/22 | 08/22 | | |
NCT05339646: A Phase I Clinical Study of SSD8432 in Healthy Adult Subjects |
|
|
| Recruiting | 1 | 108 | RoW | SSD8432 dose 1~7 and Ritonavir, SSD8432 dose 8~9, SSD8432 dose 10~12 and ritonavir, SSD8432 dose 13 and Ritonavir, SSD8432 dose 14 and Ritonavir | Jiangsu Simcere Pharmaceutical Co., Ltd. | Healthy Participants | 10/22 | 12/22 | | |
NCT05665647: Drug-Drug Interaction Study of Itraconazole, Rifampicin and Midazolam With SIM0417/Ritonavir in Healthy Participants |
|
|
| Completed | 1 | 36 | RoW | Cohort 1: SIM0417/ritonavir and itraconazole, Interaction between SIM0417/ritonavir and itraconazole, Cohort 2: SIM0417/ritonavir and rifampicin, Interaction between SIM0417/ritonavir and rifampicin, Cohort 3: SIM0417/ritonavir and midazolam, Interaction between SIM0417/ritonavir and midazolam | Jiangsu Simcere Pharmaceutical Co., Ltd. | Healthy Volunteers | 01/23 | 02/23 | | |
NCT05826249: Safety and Pharmacokinetics of SIM0417 Combined With Ritonavir in Healthy Elderly Subjects |
|
|
| Recruiting | 1 | 20 | RoW | SIM0417/Ritonavir, 750 mg SIM0417/100 mg ritonavir | Jiangsu Simcere Pharmaceutical Co., Ltd. | Elder | 09/23 | 11/23 | | |
NCT05731804: Hepatic Impairment and Renal Impairment Study of SIM0417 Combined With Ritonavir |
|
|
| Not yet recruiting | 1 | 72 | RoW | SIM0417 600 mg; Ritonavir100 mg, SIM0417 375 mg; Ritonavir100 mg, SIM0417 750 mg; Ritonavir100 mg | Jiangsu Simcere Pharmaceutical Co., Ltd. | Renal Impairment, Hepatic Impairment | 12/23 | 12/23 | | |
